2/ We've got to set realistic goals: to flatten the curve, and to suppress COVID hospitalizations & deaths.
Our health system is buckling under the weight of COVID. This is not sustainable.
The good news is that measures to control SARS-CoV-2 will also control influenza & RSV.
3/ Masking😷, ventilation🪟 & air filtration will control COVID, influenza, RSV, & other viral respiratory illnesses.
Vaccines💉, rapid antigen tests & antiviral drugs💊 can also help reduce influenza transmission, cases, hospitalizations & deaths.
4/ Our goal should be to control hospitalizations & deaths from ALL viral respiratory illnesses.
What level of hospitalizations & deaths from viral respiratory illnesses should we aim for?
We can start with what the public, health system & the economy have accepted in the past.
5/ We don't shut down the economy or society for bad flu years.
Using prior peak influenza & RSV years, we've been willing to accept a risk threshold of
~35K hospitalizations per week
& 3K deaths per week
from ALL viral respiratory illnesses.
on top of influenza & RSV hospitalizations/deaths.
7/ Risk thresholds based on hospitalizations & deaths from ALL viral respiratory illnesses would allow health departments to recommend emergency mitigation & other measures as needed.
And they're a way of measuring the success of viral respiratory illness control measures.
8/ Health systems can use risk thresholds based on hospitalizations to plan & surge bed and workforce capacity.
9/ What is the right risk threshold for hospitalizations & deaths from ALL viral respiratory illnesses moving forward?
Prior numbers are a place to start.
Different communities will have different tolerance for risk.
Ditto for hospitals & health systems.
10/ In addition to agreeing on the goals of our COVID control strategy,
we've got to rebuild public health.
11/ Need comprehensive, digital, real-time, integrated public health data infrastructure:
- national, state, local health dept data
- health care system data
- lab data, including academic & commercial
- environmental surveillance data (air, water, wastewater)
12/ Need public health workforce:
- (re)building capacity, empowering & funding health depts khn.org/news/tag/under…
- community health workers
- school nurses
Also need MORE healthcare workers in hospitals & more flexibility to move them around during emergencies as needed.
13/ Need to rebuild trust in public health institutions,
the belief that we're all in this together,
& the belief that we should & can work together in service of public health.
14/ This starts with public health systems that respond promptly, visibly, effectively in real-time to public health crises & to the needs of the community.
We've plateaued at 62% Americans fully vaccinated.
29/ We need to give a lot more boosters, especially to Americans over 50, who are at much higher risk for hospitalization and death from COVID:
30/ Depending on our goals, how immunity evolves over time after vaccination &/or infection, and how the virus mutates over time, our vaccine regimens will also evolve over time.
31/ Some vulnerable populations, especially the elderly🧓🏿, highly immunocompromised, & residents of long-term care facilities
& people in some occupations, e.g. healthcare🏥🩺, caregiving👩🏾⚕️🧑🏻⚕️
may need annual boosters💉💉💉.
34/ And that means we're unlikely to hit 90% vaccination coverage in the U.S. without other strategies.
Some other possibilities:
- Mandates (e.g. school, travel, large venues, indoor restaurants/bars/gyms/salons/spas)
- Incentives
- Voluntary
35/ The longer it takes us to⬆️COVID vaccination coverage, the longer it will take to reach endemicity and a stable steady-state with the SARS-CoV-2 virus.
36/ In the future, we may need to update our vaccines for new variants.
We should continue optimizing vaccine regimens:
- longer delay between 1st & 2nd doses
- heterologous mix & match regimens
37/ We should work on developing:
- mucosal vaccines to improve immunity in the upper airway (i.e. nose👃🏾, mouth👄, throat)
- microarray skin patches to deliver vaccine more slowly over time
- pan-sarbecovirus vaccines
38/ We need 21st-century vaccine verification systems that protect privacy & equity.
40/ In the hospital, we mostly use dexamethasone & remdesivir to treat COVID patients.
We need better-targeted immunomodulators for late-stage disease.
41/ In the out-patient setting, monoclonal antibodies work well when given early, but Omicron is resistant to our currently available monoclonal antibodies except sotrovimab.
42/ New oral antiviral drugs (Pfizer's Paxlovid & Merck's monulpiravir) are on the way, but will be will have no impact without a foundation of cheap, rapid, widely available/accessible testing & treatment:
1/ Today, the Supreme Court is considering an emergency rule issued by the Occupational Safety & Health Administration (OSHA) for workplaces with 100+ employees to require non-vaccinated employees to wear a mask at work & test negative at least weekly.
1/ CDC has shortened the recommended isolation period for COVID from 10 to 5 days
IF symptom-free at 5 days
AND recommends that people wear a mask for 5 more days.
Note that Paxlovid will initially be in short supply.
Pfizer anticipates manufacturing 80M courses of Paxlovid in 2022,
& the U.S. government has contracted to purchase 10M courses of Paxlovid (enough for 3% of the U.S. population).
Although Merck's monulpiravir has lower efficacy in preventing progression to hospitalization, it will initially be in less short supply than Paxlovid, with 10M courses available by end of 2021 and at least 20M produced in 2022.
1/ CDC has shortened the recommended isolation period for COVID from 10 days to 5 days if symptom-free at 5 days
& recommends that people then wear a mask for 5 more days.